Long-term effects of cyclic therapy with iloprost in systemic sclerosis

Abstract Views: 803
PDF: 811
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Objective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyclin, on Raynaud’s phenomenon- related symptoms and ischemic ulcers in patients with Systemic Sclerosis (SSc). Methods: A retrospective analysis of prospectively collected parameters in 59 consecutive SSc patients, followed at one institution, who were treated for a median time of 52 months with iloprost for severe Raynaud’s phenomenon and ischemic ulcers. Results: Among the 50 patients with ischemic ulcers at the start of therapy, 35 (70%) did not show lesions at the last observation. Despite therapy, four patients underwent amputations (two of forefoot, two of finger distal phalanges). Compared to the pre-treatment point, we observed: decrease of the Raynaud’s phenomenon VAS (p<0.001), and, in patients with diffuse cutaneous involvement, of the modified Rodnan skin thickness score (p=0.002). The Health Assessment Questionnaire was not significantly improved. Conclusion: Treatment with cyclic iloprost can control Raynaud’s phenomenon-related symptoms and ischemic ulcers in the large majority of patients with SSc. However, a disease-modifying effect of this therapy could not be demonstrated.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Scarsi, M., Rossi, M., Danieli, E., Frigè, A., Grottolo, A., Zambruni, A., & Airò, P. (2008). Long-term effects of cyclic therapy with iloprost in systemic sclerosis. Reumatismo, 60(2), 114–119. https://doi.org/10.4081/reumatismo.2008.114